體外和分子診斷市場正在快速增長，在大膽推進(jìn)在該醫(yī)療解決方案市場中的地位，Siemens AG已經(jīng)同意購買兩家重要的診斷公司。

在獲得Schering by BayerAG(Leverkusen, Germany)公司的認(rèn)可之后，Siemens同意以42億歐元購得Bayer醫(yī)療保健公司的診斷學(xué)分部。并購已經(jīng)得到了Bayer監(jiān)事會的批準(zhǔn)，該方案涵蓋了對許多疾病進(jìn)行評估和監(jiān)測的體外診斷產(chǎn)品，是一項龐大的投資組合。同樣在該方案中，包括了硬件、信息技術(shù)(IT)網(wǎng)絡(luò)、和復(fù)雜設(shè)備服務(wù)。Bayer公司糖尿病診斷部和Schering的診斷影像部則不包括在內(nèi)。
 
Siemens Stages Entry as New Diagnostics Powerhouse
 
In a bold push to expand the position of its Medical Solutions group in the fast-growing in vitro and molecular diagnostics markets, Siemens AG has agreed to acquire two major diagnostic companies.

Following hard on the news of the acquisition of Schering by BayerAG (Leverkusen, Germany), Siemens agreed to acquire the Diagnostics Division of Bayer HealthCare for €4.2 billion. Included in the acquisition, which has been approved by the Bayer supervisory board, is an extensive portfolio of in vitro diagnostics products for evaluating and monitoring the therapy of numerous diseases. Also included is the systems business, which includes hardware, information technology (IT) networking, and comprehensive equipment service. Not included are the Diabetes Care Division of Bayer and the diagnostic imaging business of Schering.